10-Q: Passage Bio Reports Q3 2024 Results, Outlicenses Programs to Gemma Biotherapeutics

Passage Bio announced its third quarter 2024 financial results, highlighted by a strategic outlicensing of several programs to Gemma Biotherapeutics and a restructuring of its research collaboration with Penn.

Summary

• Passage Bio reported a net loss of $19.3 million for the third quarter of 2024, compared to a net loss of $27.1 million for the same period in 2023.
• The company's research and development expenses decreased to $8.7 million in Q3 2024 from $15.1 million in Q3 2023, primarily due to reduced clinical operations and Penn expenses.
• General and administrative expenses also decreased to $7.3 million in Q3 2024 from $8.2 million in Q3 2023, mainly due to lower wages and benefits and share-based compensation expenses.
• Passage Bio outlicensed its GM1, Krabbe, and MLD programs to Gemma Biotherapeutics, receiving an initial payment of $5 million and is due an additional $5 million in December 2024.
• The company restructured its research collaboration with Penn, terminating funding for discovery research and exploratory programs.
• As of September 30, 2024, Passage Bio had $84.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations through the second quarter of 2026.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as the outlicensing deal and reduced expenses, the company's ongoing losses, reliance on external funding, and the risks associated with its product development programs temper the overall sentiment. The company is still in a precarious financial position.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Research and development expenses were significantly reduced, reflecting cost-cutting measures.
• The outlicensing agreement with Gemma Biotherapeutics provides an immediate cash infusion and potential future milestone and royalty payments.
• The restructuring of the Penn collaboration allows Passage Bio to focus on its core programs.

Negatives

• The company continues to incur significant operating losses and has an accumulated deficit of $646.5 million.
• The company is still reliant on external funding to support its operations.
• The company recognized impairment expenses for property and equipment of $2.3 million and $2.7 million for the three and nine months ended September 30, 2024, respectively.
• The company recognized impairment expenses for ROU assets of $2.5 million for the three and nine months ended September 30, 2024.

Risks

• The company's ability to generate revenue depends on the successful development and commercialization of its product candidates, which is uncertain.
• The company may not be able to obtain additional funding on acceptable terms, or at all.
• The company faces risks associated with early-stage biotechnology companies, including the need for significant additional research and development efforts and regulatory approval.
• The company's product candidates may cause undesirable side effects, which could delay or prevent their advancement into clinical trials or regulatory approval.
• The company relies on third-party manufacturers, which could lead to manufacturing problems and delays.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities, combined with the remaining initial payments for the licenses and clinical product supply in connection with the Gemma Sublicenses, and expected payments in connection with the Gemma Transition Services Agreement, will enable it to fund its operating expenses and capital expenditure requirements to the end of the second quarter of 2026.

Management Comments

• The company plans to initiate dosing in the first half of 2025 for FTD-C9orf72 patients with PBFT02.
• The company expects to obtain regulatory feedback on the clinical pathway to treating ALS patients with PBFT02 in the second half of 2024.

Industry Context

The outlicensing of programs to Gemma Biotherapeutics reflects a trend in the biotech industry where companies focus on core assets and seek strategic partnerships to advance other programs. The restructuring of the Penn collaboration is also a common strategy for companies to optimize their research and development efforts.

Comparison to Industry Standards

• The decrease in research and development expenses is consistent with cost-cutting measures seen in other biotech companies facing financial pressures.
• The outlicensing of programs is a common strategy for companies to generate revenue and focus on core assets, similar to deals made by other biotech companies.
• The company's cash runway of funding operations through the second quarter of 2026 is comparable to other companies at a similar stage of development.

Legal Proceedings

• The company is currently a defendant in litigation with a former employee in the Court of Common Pleas of Philadelphia County (Commerce Division), relating to a claim of breach of contract and violation of the Pennsylvania Wage Payment and Collection Law.
• The jury found for the plaintiff in the amount of $1.0 million on the breach of contract Claim, which the Company has accrued for and recognized in general and administrative expenses for the three and nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential future workforce reductions.
• Customers (patients) may benefit from the development of new therapies, but the timeline for commercialization is uncertain.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Report 12-month follow-up data from Cohort 1 patients and interim data from Cohort 2 patients in the first half of 2025 for the upliFT-D trial.
• Seek regulatory feedback on pivotal trial design in the second half of 2025 for PBFT02 for the treatment of FTD-GRN.
• Initiate dosing in the first half of 2025 for FTD-C9orf72 patients with PBFT02.
• Obtain regulatory feedback on the clinical pathway to treating ALS patients with PBFT02 in the second half of 2024.

Key Dates

Keywords

Passage Bio, Gemma Biotherapeutics, outlicensing, research collaboration, financial results, clinical trials, gene therapy, neurodegenerative diseases, PBFT02, FTD-GRN, GM1, Krabbe, MLD